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The particular role of the channel forming proteins in the cellular life
cycle of the virus is proposed to impose leakage upon the lipid
membranes of the host [1]. The leakage is an essential part of the viral
infection [2,3] and leads to an alteration of ionic conditions within the
infected cells, which needs to be distinct from those for the uninfected
host [4]. For some viruses these proteins are essential [5] and for others
they are just ‘only’ intensiﬁers [6]. The development of escape mutants
under the currently existing antiviral therapy which is directed mostlyagainst other proteins than channel proteins makes those of cause
highly attractive target sites for the ever pressing need of novel antiviral
and also especially antiretroviral drug candidates. Membrane proteins
in general are more conserved than soluble proteins, a fact which relies
on the structuralmotif of the transmembranedomains (TMDs) allowing
for less mutational ﬂexibility without causing disease [7].
Sequence alignment of Vpu from HIV-1 with a toxin and a series of
ion channels of the host is reported to assess structural and functional
motifs of Vpu. This protocol may serve as an additional tool for the
analysis of other viral channel proteins enabling their classiﬁcation.
1.1. Viral channel forming proteins
Viral membrane proteins can be subdivided into four classes:
(i) large proteins which are involved in viral entry and reported as
562 W.B. Fischer, H.-J. Hsu / Biochimica et Biophysica Acta 1808 (2011) 561–571fusion proteins, and mostly small to medium sized proteins which
are reported as (ii) viral channel or pore forming proteins [8,9],
(iii) membrane attached [10] or (iv) membrane penetrating proteins
[11].
There are only a handful of proteins for which there is a consensus
that they form channels (for reviews see [8,9,12,13]). Mentioning the
proteins in brief, one of the proteins is M2 from inﬂuenza A [14,15]. It
is now established that M2 is a proton channel [16–18]. It is now also
suggested that the mode of action rather correlates with the one of a
proton transporter [19]. Other channels from inﬂuenza B are reported
to conduct protons, such as BM2 [20], or ions, such as NB [21]. Protein
p7 from HCV [22,23], 2B from Polio virus [24], 3a [25] and E protein
[26] from SARS-CoV are potential channel proteins. Plant viruses also
encode a complement of a potassium channel, Kcv [27,28]. Vpu from
HIV-1 is heavily debated whether it is forming a channel or whether
this is just one of its roles in the cellular life cycle. Possibly on the
boarder-line of being a channel with a stable more or less deﬁned
diameter is Vpr from HIV-1. Vpr has been shown to exhibit channel
activity [29,30]. It is also considered that the protein harbors the
capability to traverse through the membrane [31].
For some of the channels (see also [32]) the correlation between
channel and the role in the life cycle is fairly established, and for
others it still needs to be established. In general, change of
electrochemical or substrate gradients can lead to an alteration of
conformation or folds of other proteins which then trigger secondary
events such as fusion (see the role of M2) or ion channel activity. The
latter may affect Na+, K+, or Ca2+ regulation in the infected cell.
Two names are used in the literature when reporting about these
proteins: viroporins [8] and ‘viral ion channels’ [9,33]. The ﬁrst
classiﬁcation is based on experimentswhich indicate that viral infection
impose leakage upon cell membranes which allow otherwise imper-
meable compounds to permeate [34]. More recent experiments were
done with Polio virus indicating that upon 2B deletion permeability of
infected HeLa cells to outside compounds is reduced [1]. Permeability
essays reveal that a cut-off in size for the permeating substrates exists
[35,36]. The second classiﬁcation is based on proteins reconstituted into
artiﬁcial lipid bilayers [37], a technique which has been widely used in
veriﬁcation of channel activity and selectivity [22,33,38–41].1.2. Channel–pore dualism
In the classical sense an ion channel is a membrane protein,
enabling passive diffusion of ions across the lipid membrane [42]. Ion
channels show more or less precise ion selectivity and gating and can
be selectively blocked by small molecules. The mode of action can be
triggered either by voltage gradients of small molecule ligands or
mechanical stress. The consequence of channel activity is an alteration
of electrochemical gradients across those lipid membranes which
harbor the proteins. Channels are mostly found to be involved in the
electrochemical signal transduction in nerve ﬁbers and in the brain or
they are taking part of the signal transformation cascade in the retina.
In general they are involved in a very speciﬁed mode of action which
is driven by their ion selectivity and speciﬁc mode of activation.
On the other end of the ‘precision scale’ are the ‘pores’ such as
antimicrobial peptides and toxins [43–45]. These proteins are released
into and diffuse through an aqueous phase, attach and ﬁnally in-
tegrate into the lipid membrane [46,47]. Once assembled into homo
oligomeric units they enable the ﬂux of ions and small compounds
across the lipid membrane in an ‘uncontrolled’ manner. No speciﬁc
action is requested because simply the function of these proteins is to
‘kill’ the attacked cell via draining the cytosol of the cell.
Still the question remains, when exactly will be a short protein
classiﬁed as an ion channel [48] and when do we talk about a protein
as ‘pore-like’. And more pressing, which technique should be used to
decide on this issue. Neither techniques, permeability essays, bilayerrecordings nor patch-clamp techniques with cells over expressing the
respective proteins are free of pitfalls.
May be sequence features and structural models may help to
classify the proteins to either side. Viroporins or channels are man-
ufactured to be embedded within the membrane. The modes of action
as for peptide antibiotics may ﬁnd only limited applicability to
describe the mode of action of the channel proteins. The way of how
these proteins can assemble needs to be considered in more detail for
suggesting a solution. For a single TMD it is hard to envision that in a
homooligomeric assembly some of them suddenly may induce the
formation of lipoidic pores such as the peptide antibiotics whilst the
others are not. It rather remains interesting to analyze whether the
formation may lead to a ‘pore’ or ‘channel’ at all. With two TMDs
within a protein one helix could eventually behave ‘detergent’ like. 2B
from Poliovirus may show such a dual-type of TMD system [49]. With
3 TMDs, such as in 3a from SARS-CoV, it may be worthwhile to
compare the channel proteins with the larger host channels. The
question remains whether we see a range of possible features where
each of the features is limited to one particular protein. Or is it
possible that a single protein covers multiple features and behaves
channel/porin or detergent-like?
Based on a recent investigation it has been suggested that at least
one of the proteins, may show a channel–pore dualism [40]. The
proposal is based on conductivity experiments with a peptide re-
presenting the ﬁrst 32 amino acids of Vpu from HIV-1, Vpu1–32,
reconstituted into artiﬁcial lipid bilayers. The peptide, assumed to
form bundles, shows conductance pattern in aqueous solutions of
different alkali salts which reﬂect very weak selectivity. Selectivity in
the pore is not driven by any strong electrostatic interaction of the
permeating ion and the pore wall. It is also observed that the
conductance is due to the simultaneous ﬂow of cations and anions
during an opening event. This will not allow for high selectivity and
needs the respective pore diameter to be wide enough so that
possibly also small molecules may permeate. Such an idea is
supported by ﬁndings for 2B from Polio virus with 2 TMDs, where
the pore size of the potential pore allows for size dependent
substrate diffusion [35]. Structural data of the membrane morphol-
ogy of 2B are not yet available. It is still an option for the 2B channel
to adopt a ‘carpet’ like morphology [47] with one of the helices
lying onto or strongly exposed to the membrane surface. A similar
topology and uncertainty of membrane morphology like for 2B holds
for p7 from HCV. In the case of the latter experimental data from cryo
electron microscopic suggest that the two TMDs align antiparallel
when in detergent environment [50]. Again, the question remains,
whether this is the only morphology or can p7 also adopt various
conformations under speciﬁc in vivo conditions. The concept of a
weak channel with the consequence of a channel–pore dualism may
not hold for all channels. With increasing TMDs per monomer, the
likely-hood may vain. Hither forth the name ‘channel’ is used for the
proteins for simplicity.
2. Sequence alignment of Vpu with toxin and ion channels
The primary sequence of Vpu is aligned with ion channels and a
toxin in anticipation that an environmental constraint spurs the
development of a speciﬁc sequence and with it a similar structure
within a protein. The focus is on the TMD of the proteins and therefore
the ion channels chosen are those which adopt a helical TM motif
similar to Vpu. The aligned TMDs are highlighted in the 3D structures
of the respective channels and the toxin.
Sequence alignment of a representative number (10 isolates) of
Vpu proteins (80 and 81 amino acids) taken from the Universal
Protein Resource (UniProt) (www.uniprot.org) displays a large
number of identical residues (10 residues) and conserved substitution
(7 residues) within the hydrophobic TM region of Vpu6–27 (Fig. 1A).
HV1B8 and HV1SC isolates show insertions of threonine and serine,
Fig. 1. Sequence alignment (A) and cladogram (B) of a representative number of Vpu isolates (10 Vpu isolates) derived from the Universal Protein Resource (UniProt) (www.uniprot.
org) and GenBank (www.ncbi.nlm.nih.gov for AAB59750.1) using ClustalW2 2.0.12 (www.ebi.ac.uk). Abbreviations and colors according to ClustalW2: ‘*’=identical residues;
‘:’=conserved substitution; ‘.’=semi-conserved substitution; hydrophobic, aromatic (not Y) and small residues (AVFPMILW (single letter code)) are shown in red.
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HV1Z3 and HV190, replace Ile-24 by tyrosine at the C terminal side of
Vpu6–27. Two isolates replace Ile-15 (HV1MN) Ala-7 as well as Val-
8 (HV190) by glycine. A cladogram indicates that based on the amino
acid sequence the different isolates adopt a very common ances-
try (Fig. 1B). The numbering scheme mentioned refers to isolate
AAB59750.1 (GenBank: AAB59750.1, www.ncbi.nlm.nih.gov) [51]
which is taken as the sequence for alignment with the channels and
toxin. Based on the almost perfect alignment the original isolate
AAB59750.1 is chosen as an adequate representative of Vpu for
sequence alignment with other channel and toxin proteins.
The following proteins have been used for sequence alignment
with Vpu isolate AAB59750.1: cytolysin A (ClyA, toxin) [52], acid-
sensitive potassium channel protein (TASK, UniProtKB/Swiss-Prot
O14649, www.uniprot.org) [53], K+ channel from Streptomyces
lividans (KcsA, PIR S60172) [54], nicotinic acetylcholine receptor
(nAChR) [55], α-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid (AMPA)-sensitive, homotetrameric, rat glutamate A2 receptor
(GluA2) [56], prokaryotic pentameric ligand gated ion channel
(pLGIC) [57], pentameric formate channel (pFC) [58], large-conduc-
tance mechanosensitive channel (MscL) [59], 3a from SARS-CoV
(GenBank: ABA02268.1, www.ncbi.nlm.nih.gov) [60] and bone
marrow stromal antigen 2 (BST-2, UniProtKB/Swiss-Prot Q10589,www.uniprot.org) [61]. Proteins have been pair wise aligned using
ClustalW2 2.0.12 (www.ebi.ac.uk).
Sequence alignment of Vpu (Vpu1–81) with ClyA [52] shows no
overlap of the TMD of Vpu with any parts of the toxin which is
proposed to point into the lipid membrane (data not shown). When
restricting the alignment to the ﬁrst 100 amino acids of ClyA the
hydrophobic part of the TMD of Vpu (Vpu6–27) has a considerable
overlap with αA (residues 11–34) which is within the membrane in
the assembled protein (Fig. 2A). The sequenceαD/αE (residues 164 to
206) which is also suggested to interact with the membrane only
slightly aligns with the C terminal side of Vpu (VpuW22–K31) (data
not shown). The alignment leads to a break in the ClyA chain.
Comparison of the sequence of Vpu with human TASK-1 generates
no alignment with the TMDs suggested by Hsu et al. [53] (data not
shown). Aligning full length Vpu with the ﬁrst 100 amino acids of
TASK-1 reveals a match of the ﬁrst 32 amino acids of both sequences
as suggested by Hsu et al identifying 6 identical residues (Fig. 2B). The
proposed TMD of TASK-1 (Leu-9–Glu-30) overlaps with the TMD of
Vpu, residues Ala-9 to Arg-30. In the case of KcsA [54] residues Ile-19
to Ser-23 of Vpu and Ala-12 to Arg-27 of KscA, as well as Ile-24 to Glu-
28 of Vpu and Ile-38 to Ala-42 of KcsA alignwith one and two identical
residues, respectively (Fig. 2C). This match is independent of the
sequence used for either Vpu or KcsA. The structural motif indicates
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Fig. 2. Similarity of Vpu [51] and various parts of it with respective toxin and non viral channel proteins. For detailed naming of the proteins see table caption of Table 1. Abbreviations
and colors according to ClustalW2: ‘*’=identical residues; ‘:’=conserved substitution; ‘.’=semi-conserved substitution; hydrophobic, aromatic (not Y) and small residues
(AVFPMILW) are shown in red. The red bars indicate helical TMD of the proteins. The helices of the toxin and the non viral channels are named according to their respective notation
in the literature.
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KcsA.
Alignment of Vpu with the primary sequence of either of the three
ligand gated ion channels nAChR, GluA2 and pLGIC reveals no overlap
with any of the individual TMDs of these channels (data not shown).
Restricting the Vpu sequence to the ﬁrst 30 amino acids, then an
overlap with the TMDs of the ligand gated channels is observed.For nAChR sequence A/D (Fig. 2D) the N terminal side of Vpu3–12
matches parts of M1 (Pro-211–Ile-220), whilst the C terminal side,
Vpu13–30, overlaps with M2 (Ile-247–Ile-264) (Fig. 2D, Sequence A/D,
I). Omitting Vpu1–5 and Vpu28–30 leads to an extended overlap of the C
terminal side of Vpu6–27 with M2 and a rather weak overlap of the N
terminal side of Vpu6–27 with M1 (Fig. 2D, Sequence A/D, II).
The remaining sequences have in common an overlap of the TMD of
Fig. 2 (continued).
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overlaps with the C terminal side of the TMD of Vpu6–27 (Fig. 2D,
Sequence B, I and II). Residue identity of Vpu6–27-W22 with
tryptophans of sequence C (Trp-331) and E (Trp-333) leads to
disruption of Vpu6–27 and a consequent overlap of Vpu6–27 with M4
(Fig. 2D, Sequences C and E (II)). Alignment of Vpu1–30 with sequences
C and E identiﬁes an overlap mostly with M3 including also the
C terminal side of M2 (Fig. 2D, Sequence E I). Favoring minimum
disruption, overlapping of Vpu6–27 with the sequences of nAChR sheds
light of a potential overlap with M2 and M3.
The sequence of GluA2 allows an overlap rather with the Pre-M1
and N terminal side of the M1 domain of the receptor with the C
terminal side of the TMD of Vpu18–31 (Fig. 2E, I). Removing the ends inthe Vpu sequence as mentioned for nAChR-Vpu alignment, shifts the
overlap rather towards the N terminal side of the receptor which
barely includes still the Pre-M1 domain (Fig. 2E, II).
Alignment of the Vpu1–30 sequences with pLGIC results in a split of
the Vpu sequence into three parts aligning with parts ofα1 (Vpu1–10),
α2 (Vpu11–23) and α3 (Vpu24–30) (Fig. 2F, I). The shorter Vpu6–27
segment aligns solely with the α1 domain (Fig. 2F, II). For all three
receptors the overlap of the longer sequence is driven by the Glu-Tyr-
Arg (EYR-motif) of Vpu, whilst in the case of Vpu6–27 Trp-22 is the
driving amino acid for a consensus alignment. The overlap is with the
domain which is at the outside of each of the subunits.
Unbiased alignment of Vpu with pFC results in an overlap of
residues pFC-Ile-195 to pFC-Ser-204, which are allocated to the 5a
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pFC overlaps with Vpu11–9. Vpu6–27 aligns this segment with pFC
domain 4 (Fig. 2G, II). This is driven by overlap of Vpu-Trp-22 with
pFC-Trp-231. Mutating Vpu-Trp-22 into alanine aligns the Vpu
sequence Vpu6–27 with the pFC 2a domain (Fig. 2G, III). The result is
that solely the TMD of Vpu has high sequence identity with an outside
facing domain of pFC.
Unbiased sequence alignment of Vpu with TMD2 of MscL shows
sequence identity with the TMD of MscL (Fig. 2H, I). A truncated
sequence of MscL, MscL1–100, aligns the N terminal side of M-TMD1
with the C terminus of the Vpu-TMD (Fig. 2H, II). Aligning only the
ﬁrst 30 aa of Vpu with MscL1–174 delivers a match of both C termini of
the TMD of Vpu with TMD2 (outer helix) of MscL (Fig. 2H, III).
Sequence alignment of Vpu with 3a reveals overlap with the
proposed TMD3 of 3a and the cytoplasmic part of 3a (Fig. 2I, I). When
aligned with the 3a1–150, the C terminal part of Vpu-TMD aligns with
the N terminal part of 3a-TM1 (Fig. 2I, II). Taking Vpu1–32 overlap with
the entire TMD1 of 3a is achieved (Fig. 2I, III). For Vpu6–27 the N
terminal side (Vpu6–15) matches with the C terminal side of 3a 3a-
Leu-41 to 3a-Val-50 (Fig. 2I, IV). The position of TMD1 of 3a within the
putative bundle is still under investigation and proposed to be at the
outer side of the bundle [62].
Alignment of Vpu with TMD of BST-2 is almost a perfect match
(Fig. 2J).
2.1. Maximum overlap of the TMDs of Vpu with those of the toxin and ion
channels
Alignment of Vpu6–27 with the selected proteins in this study
reveals a maximum overlap with the TMD of pLGIC (Table 1). The
TMDs of Vpu6–27 and α1 of pLGIC match over the entire 22 amino
acids of α1with only a single gap of only a single amino acid. TMD1 of
TASK overlaps with 19 amino acids followed by BST-2 and MscL both
showing 17 amino acids overlap of their TMD and TMD2, respectively.
The nAChR and 3a still align 17 and 16 amino acids, respectively, with
Vpu6–27. For nAChR the match is most pronounced for M2 (sequence
A/D) followed byM3with amatch of 16 amino acids (sequences C and
E). Sequence B allows 10 amino acids of Vpu6–27 to match with its M3
segment. With ClyA and pFC 15 and 14 residues, respectively, overlap,
followed by GluA2 (10 amino acids) and KcsA (9 amino acids). Whilst
for all channels mentioned just single gaps with up to 4 amino acids
are observed, the TMD of KcsA is interrupted by a single gap of 10
amino acids of the channel. Ranking the perfect matches a sequence
of MscL (7 matches), nAChR-C and TASK (5 matches each), pFC
(4 matches), 3a, KcsA, pLGIC and nAChR-E (3 matches each). Taking
maximum overlap and number of identical residues as a margin,Table 1
Similarity of Vpu6–27 [51] with respective toxin and non viral channel proteins: ClyA [52], TAS
CoV [60] and BST-2 [61]. Entry code in the protein data bank (www.rcsb.org) is given in brac
conserved substitution; ‘–‘ = no speciﬁcation suggested; ‘TMD’ = transmembrane doma
respective sequence number in the literature. WFY single letter code.
aa of Vpu which overlap * :
ClyA; [2WCD] αA 15 2 2
TASK; TMD1 19 5 6
KcsA; [1BL8] outer helix 9 3 3
nAChR; [2BG9]
A,D: M1/M2 5/17 –/4 2/9
B: M3 10 – 8
C: M3/M4 16/4 5/2 6/1
E: M3/M4 16/4 3/1 8/2
GluA2; [3KG2] Pre-M1/M1 10 2 4
pLGIC; [2VL0] α1 22 3 9
pFC; [3KLY] TM4 14 4 4
MscL; [2OAR] TMD2 17 7 6
3a; TMD1 16 3 5
BST-2; TMD 17 4 8pLGIC, TASK and MscL adopt the highest rank (‘top three’). All
channels in common are an alignment driven by matches with
tryptophans, phenylalanines and tyrosines of the respective channels
with W-22 of Vpu6–27.
Highlighting the respective TMDs of each of the toxin and channels
with which Vpu6–27 overlaps reveals that these TMDs are not always
pore lining (Fig. 3A–C, orange helices). From the ‘top three’, pLGIC and
MscL havematching TMDs rather at the outside of theproteins (Fig. 3B,
C). For pFC thematch is with the P segmentwhich if fully embedded in
the structure (Fig. 3C). A match with the pore lining domains is only
found for two of the segments of the nAChR (Fig. 3B). Also for ClyA the
matching segmentαA is a pore facingpart of the giant pore (Fig. 3A). In
most of the cases the TMD of Vpu matches with outside or embedded
TMDs of the channels. For nAChR a duality is detected. It is concluded
that the motif of the TMD of Vpu most likely harbors the capability of
diffusing as a non-channel with some expertise to form a conducting
channel. Channel formation need possibly speciﬁc conditions in vivo,
such as lipid composition and dynamics or possibly also co-factors
such as host membrane proteins or rafts to adopt a fully functional
pore. For 3a the pore lining TMD is still to be elucidated, however the
proposal of amatchwith TMD1does notmatchwith a proposedmodel
in which TMD3 is pore lining [62] (Fig. 3C).
3. Structural modeling with in silico methods
The most advanced structural data are available for M2 from
inﬂuenza A [63] and Vpu from HIV-1 [64] based on NMR studies. Most
recently X-ray [65] and solution NMR structures [66] have been
reported on M2 which deliver bundle structures even in the presence
of drug candidates. Also for M2 of inﬂuenza B, BM2, a structure of the
assembled TMDs including the cytoplasmic domain resolved with
solutionNMRspectroscopy is at hand [67]. The channel protein p7 is so
far enlightened by cryo electron microscopy identifying its potential
number of assembled units per channel to be most likely hexameric
[23,50], albeit heptameric assemblies have also been reported [68].
On the computational level there are many options to achieve
potential bundle models. One of the options is that the protocol for
assembly can follow in vivo pathways as best as possible. This is that
the protein momoners are produced in the endoplasmic reticulum
(ER), diffuse within the ER and either interact – assemble –with other
proteins, such as host proteins, or assemble with each other into
homooligomers. In the latter case there can be pathways in which a
putative bundle or monomeric unit is assembled by simultaneously
approach of all units (concerted pathway). Alternatively, and most
likely, the monomers assemble in a sequential manner (sequential
pathway).K [53], KcsA [54], nAChR [55], GluA2 [56], pLGIC [57], pFC [58], MscL [59], 3a from SARS-
kets. ‘aa’= amino acid; ‘*’= identical residues; ‘:’= conserved substitution; ‘.’= semi-
in. The helices of the toxin and the non viral channels are named according to their
. – Gaps aa in gaps Aromatic aa
4 7 – – –
1 7 – – –
– 2 1 10 W
1/1 2/2 –/– –/– –/F
– 2 – – F
3/1 2/– 1/– 2/– –/W
2/– 3/1 1/– 4/– –/W
– 4 – – W
3 7 1 1 W
3 2 – – W
2 2 1 3 Y
2 4 1 2 W
3 2 1 2 F
Fig. 3. The toxin ClyA and the channel protein KcsA are shown in a side view (left) and a view from the respective top (middle) and bottom (right) of the protein (A). For the channel
proteins only the TMDs are shown. The TMDs of nAChR, GluA2 and pLGIC are shown in the same way (B), so are the TMDs of the formate channel, MscL and 3a (C). The proteins are
shown in green with the helical backbones sketched. Overlapping domains with Vpu6–27 are highlighted in orange.
568 W.B. Fischer, H.-J. Hsu / Biochimica et Biophysica Acta 1808 (2011) 561–571Most of the computational techniques adopted follow a kind of
concerted pathways [69–74]. All potential TMDs are aligned and in a
more or less ﬁne grained step-width in respect of distances and angles.
Conformational space is screened resulting in a moderate number ofpotential models. Ranking according to calculated potential energies
allows the most appropriate model to be chosen also in accordance
with all necessary constrains relatedwith the general idea of a channel.
In a more recent study the tetrameric M2 channel has been obtained
569W.B. Fischer, H.-J. Hsu / Biochimica et Biophysica Acta 1808 (2011) 561–571from a replica exchange approach [75]. Also here an enormous amount
of conformational space is screenedwhich depend nevertheless on the
initial starting conﬁguration.
In a more recently assembly method which is best described as a
positioning approach combined with short energy minimization an
extremely large number of structural models is achieved [62]. In this
method positioning is done for the backbone structure of a speciﬁc helix.
The backbone structure is derived from a classical MD simulation of the
monomer or monomeric unit embedded in a fully hydrated lipid bilayer.
All the structures from the MD simulation are due to a principle com-
ponent analysis (PCA). The framesbelonging to theﬁrst eigenvector of the
covariance matrix are averaged and used in the assembly method.
Positioning is based on a rotational matrix for the Cα atoms in which
rotational symmetry, tilt and rotation is altered with an angle and step
widths chosenby theoperator. In the assemblyprotocol for eachposition-
ing the side chains are consequently ‘attached’ to the individual Cα atoms
on the bases of the most probably conﬁguration taken from the software
data base (MOE, www.chemcomp.com). At this stage short energy
minimization steps follow and the models are ranked according to their
potential energy. Structural integrity [76] or ion selectivity [77] of selected
models can be further assessed stressing MD simulation techniques.
In the above mentioned assembly protocols all helices in a larger
assembly, e.g. four or ﬁve helices, are moved, tilted or rotated simul-
taneously and in the same direction (concerted pathway). Sequential
pathways have been so far rarely applied. It can be argued that it ismost
unlikely that all TMDs assemble at once. Most likely it seems that
possibly two TMDs approach each other followed by either monomeric
or dimeric TMDs and also oligomeric units. Along this line investigations
have been conducted in which the alignment of themonomeric units of
the three TMDs of 3a follows the so call sequential pathway (Hsu and
Fischer; to be published).
For most of the models a helical motif of the TMD is assumed. In
another approach using coarse-grained techniques the insertion and
consequent formation of the secondary structural element is left to ‘in
silico’ calculations [78]. The formation is dependent on the quality of
the force ﬁeld based forces present in the environment of a lipid
bilayer. Starting from a random structure outside the membrane Vpu
from HIV-1 is seen to enter the membrane and adopt indeed a helical
formation [78]. Simulations on other proteins such as glycophorin
have proven that coarse-grained methods are reliable when assem-
bling two TMDs from random positions. [79].
4. Drugs
Membrane proteins exhibit a variety of potential target sites.Most of
these proteins express a considerable extramembrane domain which
can be investigated separately from the TMDs. Usually crystallography
and NMR spectroscopy can be used to obtain high resolution structural
information followed by classical docking approaches for screening of
the extramembrane parts of the proteins. Also the TMDs of these
proteins may harbor potential target sites as has been shown recently
with experiments forM2 of inﬂuenza A on a structural level [65,66]. The
antiviral drug amantadine has been detected inside the tetrameric
bundle of M2 [65] which is in accordance with other experimental [80–
82] and computational evidence [83]. In a most recent solid state NMR
investigation amantadine is found at both an inside and outside pose
[84]. The outside location of amantadine is detected to be on the ‘surface
of the protein’which is in contrast to the reported outside binding site of
rimantadinewhich is identiﬁed to be at the protein–lipid interface [66].
Adetailed evaluationof the currently ongoing controversy over the drug
binding site in M2 is reviewed elsewhere [85]. The conclusion from the
current discussion in the ﬁeld is that for future modeling of drug–
protein interaction the lipid environment has to be more thoroughly
taken into account in drug development.
Amantadines have been reported to become inefﬁcient due to
mutations within the TMD of M2 [86,87]. Computational investiga-tions reveal the reason for drug resistance is steric impair due to
mutation at particular binding sites within the pore (see Khurana
et al., this issue). Spiro-piperidines have been suggested as novel
small molecule drugs to overcome viral resistance and reported to
bind within the TMD of the M2 bundle [88].
Similarly, for Vpu from HIV-1 binding sites of potential drug
candidates such as derivatives from amiloride are also reported to
have the potential of inside and outside binding sites when docked to a
pentameric bundle of theTMDofVpu [89,90]. Outsidebinding siteshave
been found as lowest poses for some of the compounds investigated.
Blocking of hexamethylene amiloride has also been reported experi-
mentally with a peptide corresponding to the TMD of Vpu [91]. For p7 a
series of drugs have been found to affect channel activity when p7 is
reconstituted into artiﬁcial lipid membranes. The drugs identiﬁed are
iminosugars [22,92], amantadine [23,92], hexamethyleneamiloride [93]
and most recently substituted napthoyl guanidines [94]. A speciﬁc
binding site is so far proposed for amantadine to be inside a potential
computationally derived hexameric p7 model [73]. A direct link
between the modulator effects on Vpu and p7 found in vitro and in
vivo affects has yet to be established.
With the most recent ﬁndings that Vpu interacts with host factors
such as BST-2 [95,96] or eventually with TASK [53] via a potential
interaction of its TMD with those of the host proteins sparks the idea
to target the viral proteins from ‘within’ [13,97]. Here ‘within’ means
the lipid membrane with the drugs preventing the oligomerization of
the target protein either with itself or with the host. These ‘anti-
oligomerization’ drugs (AODs) may either be peptides (anti-
oligomerization peptide drugs (AOPDs), mimicking the potential
interaction-partner in its sequence and conformation, or again small
molecule drugs derived from conventional sources such as drug
design, derivatives of existing drugs or herbs. Since screening for drug
candidates needs to take the environment of the lipid membrane
more thoroughly into account, this consequently imposes novel
aspects on the docking approach. Peptide drugs have so far been
reported to be a successful approach when interfering with the mode
of action of fusion proteins from paramyxoviruses [98], HBV [99] or
gp41 from HIV-1 [100] and one of HIV's entry receptor protein [101].
In all cases the peptide drug mimics parts of the viral fusion protein.
Also membrane active proteins such as Nef from HIV are suggested to
be the target of antiviral peptide drugs [102].
5. Conclusions
Some of the viral channel proteins are multi tasking such as Vpu or
Vpr, and some are known only in their role as a channel protein. In the
latter case the protein consists of multi TMDs or as in the case of a
single TMD (M2 from inﬂuenza A) is covalently coupled to a
neighboring protein of the same kind (dimer of a dimer). Thus,
increasing number of TMDs goes alongside with speciﬁcity. The single
TMD protein Vpu shows motifs similar to pore lining helices but most
likely also motifs of outer helices of large ion channels, which
surround the pore lining helices. This supports a dual mode of action.
Despite the tremendous success in viral channel research, questions
remain, about the condition which is needed for the protein to ﬁnally
start conducting ions after assembly. Is the ‘proper’ assembly already
done during themode of assembly or is there a reshufﬂing of the helices
whenassembled? Is eventually the reshufﬂingmodulated by someother
factors? Still an unknown ﬁeld is the contribution of the extramembrane
parts of the proteins. So far most of the results are based on separate
investigations on either the TMDs or the cytoplasmic parts.
Acknowledgements
WBF and HJH thank the Taiwanese Government (Aim of
Excellence Plan) and the National Science Council (NSC) of Taiwan
(NSC98-2112-M-010-002-MY3) for ﬁnancial support.
570 W.B. Fischer, H.-J. Hsu / Biochimica et Biophysica Acta 1808 (2011) 561–571References
[1] R. Aldabe, A. Barco, L. Carrasco, Membrane permeabilization by poliovirus
proteins 2B and 2BC, J. Biol. Chem. 271 (1996) 23134–23137.
[2] L. Carrasco, The inhibition of cell functions after viral infection, FEBS Lett. 76
(1977) 11–15.
[3] C.N. Nair, Na and K changes in animal virus-infected HeLa cells, J. Gen. Virol. 65
(1984) 1135–1138.
[4] L. Carrasco, A.E. Smith, Sodium ions and the shut-off of host cell protein synthesis
by picornaviruses, Nature 264 (1976) 807–809.
[5] A. Sakai, M. St. Claire, K. Faulk, S. Govindarajan, S.U. Emerson, R.H. Purcell, J. Bukh,
The p7 polypeptide of hepatitis C virus is critical for infectivity and contains
functionally important genotype-speciﬁc sequences, Proc. Natl. Acad. Sci. USA
100 (2003) 11646–11651.
[6] K. Strebel, T. Klimkait, M.A. Martin, Novel gene of HIV-1, vpu, and its 16-
kilodalton product, Science 241 (1988) 1221–1223.
[7] A. Oberai, N.H. Joh, F.K. Pettit, J.U. Bowie, 17747–17750, Structural imperatives
impose diverse evolutionary constraints on helical membrane proteins, Proc.
Natl Acad. Sci. USA 106 (2009) 17747–17750.
[8] M.E. Gonzales, L. Carrasco, Viroporins, FEBS Lett. 552 (2003) 28–34.
[9] W.B. Fischer, M.S.P. Sansom, Viral ion channels: structure and function, Biochim.
Biophys. Acta 1561 (2002) 27–45.
[10] J.F. Roeth, K.L. Collins, Human immunodeﬁciency virus type 1 Nef: adapting to
intracellular trafﬁcking pathways, Microbiol. Mol. Biol. Rev. 70 (2006) 548–563.
[11] A. Fittipaldi, M. Giacca, Transcellular protein transduction using the Tat protein
of HIV-1, Adv. Drug Deliv. Rev. 57 (2004) 597–608.
[12] W.B. Fischer, Viral membrane proteins: structure, function and drug design, in:
M.Z. Atassi (Ed.), Protein Reviews, Vol. 1, Kluwer Academic / Plenum Publisher,
New York, 2005, p. 291.
[13] W.B. Fischer, J. Krüger, Viral channel forming proteins, Int. Rev. Cell. Mol. Biol.
275 (2009) 35–63.
[14] H. Allen, J. McCauley, M. Waterﬁeld, M. Gethering, Inﬂuenza virus RNA segment
7 has the coding capacity for two polypeptides, Virology 107 (1980) 548–551.
[15] G. Winter, S. Fields, Cloning of inﬂuenza cDNA into M13: the sequence of the
RNA segment encoding the A/PR/8/34 matrix protein, Nucl. Acids Res. 8 (1980)
1965–1974.
[16] C. Schroeder, C.M. Ford, S.A. Wharton, A.J. Hay, Functional reconstitution in lipid
vesicles of inﬂuenza virus M2 protein expressed by baculovirus: evidence for
proton transfer activity, J. Gen. Virol. 75 (1994) 3477–3484.
[17] J.A. Mould, H.C. Li, C.S. Dudlak, J.D. Lear, A. Pekosz, R.A. Lamb, L.H. Pinto,
Mechanism for proton conduction of the M2 ion channel of inﬂuenza A virus,
J. Biol. Chem. 275 (2000) 8592–8599.
[18] T. Lin, C. Schroeder, Deﬁnitive assignment of proton selectivity and attoampere
unitary current to the M2 ion channel protein of inﬂuenza A virus, J. Virol. 75
(2001) 3647–3656.
[19] E. Khurana, M. Dal Peraro, R. De Vane, S. Vemparala, W.F. DeGrado, M.L. Klein,
Molecular dynamics calculations suggest a conductance mechanism for the M2
proton channel from inﬂuenza A virus, Proc. Natl Acad. Sci. USA 106 (2009)
1069–1074.
[20] J.A. Mould, R.G. Paterson,M. Takeda, Y. Ohigashi, P. Venkataraman, R.A. Lamb, L.H.
Pinto, Inﬂuenza B virus BM2 protein has ion channel activity that conducts
protons across membranes, Dev. Cell 5 (2003) 175–184.
[21] W.B. Fischer, M. Pitkeathly, B.A. Wallace, L.R. Forrest, G.R. Smith, M.S.P. Sansom,
Transmembrane peptide NB of inﬂuenza B: a simulation, structure, and
conductance study, Biochemistry 39 (2000) 12708–12716.
[22] D. Pavlovic, D.C.A. Neville, O. Argaud, B. Blumberg, R.A. Dwek, W.B. Fischer, N.
Zitzmann, The hepatitis C virus p7 protein forms an ion channel that is inhibited
by long-alkyl-chain iminosugar derivatives, Proc. Natl Acad. Sci. USA 100 (2003)
6104–6108.
[23] S.D.C. Grifﬁn, L.P. Beales, D.S. Clarke, O. Worsfold, S.D. Evans, J. Jäger, M.P.G.
Harris, D.J. Rowlands, The p7 protein of hepatitis C virus forms an ion chan-
nel that is blocked by the antiviral drug, amantadine, FEBS Lett. 535 (2003)
34–38.
[24] A.S. de Jong, E.Wessels, H.B.P.M. Dijkman, J.M.D. Galama,W.J.G. Melchers, P.H.G.M.
Willems, F.J.M. van Kuppeveld, Determinants for membrane association and
permeabilization of the coxsackievirus 2Bprotein and the identiﬁcationof theGolgi
complex as the target organelle, J. Biol. Chem. 278 (2003) 1012–1021.
[25] W. Lu, B.-J. Zheng, K. Xu, W. Schwarz, L. Du, C.K.L. Wong, J. Chen, S. Duan, V.
Deubel, B. Sun, Severe acute respiratory syndrome-associated coronavirus 3a
protein forms an ion channel and modulates virus release, Proc. Natl Acad. Sci.
USA 103 (2006) 12540–12545.
[26] L. Wilson, C. McKinlay, P. Gage, G. Ewart, SARS coronavirus E protein forms
cation-selective ion channels, Virology 330 (2004) 322–331.
[27] B. Plugge, S. Gazzarrini, M. Nelson, R. Cerana, J.L. Van Etten, C. Derst, D.
DiFrancesco, A. Moroni, G. Thiel, A potassium channel protein encoded by
chlorella virus PBCV-1, Science 287 (2000) 1641–1644.
[28] G. Thiel, D. Baumeister, I. Schroeder, S.M. Kast, J.L. van Etten, Minimal art: or why
small viral K+ channels are good tools for understanding basic structure and
function relations, Biochim. Biophys. Acta 1808 (2011) 580–588.
[29] S.C. Piller, G.D. Ewart, A. Premkumar, G.B. Cox, P.W. Gage, Vpr protein of human
immunodeﬁciency virus type 1 forms cation-selective channels in planar lipid
bilayers, Proc. Natl Acad. Sci. USA 93 (1996) 111–115.
[30] C.P. Chen, C. Kremer, P. Henklein, U. Schubert, R.H.A. Fink, W.B. Fischer,
Modulating the activity of channels formed by a short segment of the Vpr protein
from HIV-1., Eur. Biophys. J., published online (2009).[31] M.P. Sherman, U. Schubert, S.A. Williams, C.M.C. de Noronha, J.F. Kreisberg, P.
Henklein, W.C. Greene, HIV-1 Vpr display natural protein-transduction proper-
ties: implications for viral pathogenesis, Virology 302 (2002) 95–105.
[32] K. Wang, S. Xie, B. Sun, Viral proteins function as ion channels, Biochim. Biophys.
Acta 1808 (2011) 510–515.
[33] U. Schubert, A.V. Ferrer-Montiel, M. Oblatt-Montal, P. Henklein, K. Strebel, M.
Montal, Identiﬁcation of an ion channel activity of the Vpu transmembrane
domain and its involvement in the regulation of virus release from HIV-1-
infected cells, FEBS Lett. 398 (1996) 12–18.
[34] L. Carrasco, Membrane leakiness after viral infection and a new approach to the
development of antiviral agents, Nature 272 (1978) 694–699.
[35] A. Agirre, A. Barco, L. Carrasco, J.L. Nieva, Viroporin-mediated membrane
permeabilization. Pore formation by nanostructural poliovirus 2B protein,
J. Biol. Chem. 277 (2002) 40434–40441.
[36] F.J.M. van Kuppeveld, J.G.J. Hoenderop, R.L.L. Smeets, P.H.G.M. Willems, H.B.P.M.
Dijkman, J.M.D. Galama, W.J.G. Melchers, Coxsackievirus protein 2B modiﬁes
endoplasmic reticulum membrane and plasma membrane permeability and
facilitates virus release, EMBO J. 16 (1997) 3519–3532.
[37] M. Montal, P. Müller, Formation of bimolecular membranes from lipid
monolayers and a study of their electrical properties, Proc. Natl Acad. Sci. USA
69 (1972) 3561–3566.
[38] G.D. Ewart, T. Sutherland, P.W. Gage, G.B. Cox, The Vpu protein of human
immunodeﬁciency virus type 1 forms cation-selective ion channels, J. Virol. 70
(1996) 7108–7115.
[39] T. Mehnert, Y.H. Lam, P.J. Judge, A. Routh, D. Fischer, A. Watts, W.B. Fischer,
Towards a mechanism of function of the viral ion channel Vpu from HIV-1,
J. Biomol. Struct. Dyn. 24 (2007) 589–596.
[40] T. Mehnert, A. Routh, P.J. Judge, Y.H. Lam, D. Fischer, A. Watts, W.B. Fischer,
Biophysical characterisation of Vpu from HIV-1 suggests a channel–pore
dualism, Proteins 70 (2008) 1488–1497.
[41] C.F. Chew, R. Vijayan, J. Chang, N. Zitzmann, P.C. Biggin, Determination of pore-
lining residues in the hepatitis C virus p7 protein, Biophys. J. 96 (2009) L10–L12.
[42] B. Hille, Ion Channels of Excitable Membranes, 3rd edSinauer Associates, Inc,
Sunderland, MA, USA, 2001.
[43] G.A. Woolley, B.A. Wallace, et al., Model ion channels: gramicidin and
alamethicin, J. Membr. Biol. 129 (1992) 109–136.
[44] Z. Oren, Y. Shai, Mode of action of linear amphipathic α-helical antimicrobial
peptides, Biopolymers 47 (1998) 451–463.
[45] K.A. Brogden, Antimicrobial peptides: pore formers or metabolic inhibitors in
bacteria? Nat. Rev. Microbiol. 3 (2005) 238–250.
[46] L. Yang, T.A. Harroun, T.M. Weiss, L. Ding, H.W. Huang, Barrel-stave model or
toroidal model? A case study onmelittin pores, Biophys. J. 81 (2001) 1475–1485.
[47] Y. Shai, Z. Oren, From ‘carpet’ mechanism to de-novo designed diastereomeric
cell-selective antimicrobial peptides, Peptides 22 (2001) 1629–1641.
[48] R.A. Lamb, L.H. Pinto, Do Vpu and Vpr of human immunodeﬁciency virus type 1
and NB of inﬂuenza B virus have ion channel activities in the viral life cycles?
Virology 229 (1997) 1–11.
[49] G. Patargias, T. Barke, A. Watts, W.B. Fischer, Model generation of viral channel
forming 2B protein bundles from polio and coxsackie viruses., Mol. Membr. Biol.,
accepted (2009).
[50] P. Luik, C. Chew, J. Aittoniemi, J. Chang, P. Wentworth Jr., R. Dwek, P.C. Biggin, C.
Vénien-Bryan, N. Zitzmann, The 3-dimensional structure of the hepatitis C virus
p7 ion channel by electron microscopy, Proc. Natl Acad. Sci. USA 106 (2009)
12712–12716.
[51] S. Wain-Hobson, P. Sonigo, O. Danos, S. Cole, M. Alizon, Nucleotide sequence of
the AIDS virus, LAV, Cell 40 (1985) 9–17.
[52] M. Müller, U. Grauschopf, T. Maier, R. Glockshuber, N. Ban, The structrure of a
cytolytic alpha-helical toxin pore reveals its assembly mechanism, Nature 459
(2009) 726–730.
[53] K. Hsu, J. Seharaseyon, P. Dong, S. Bour, E. Marbán, Mutual functional destruction
of HIV-1 Vpu and host TASK-1 channel, Molec. Cell 14 (2004) 259–267.
[54] D.A. Doyle, J.M. Cabral, R.A. Pfuetzner, A. Kuo, J.M. Gulbis, S.L. Cohen, B.T. Chait, R.
MacKinnon, The structure of the potassium channel: molecular basis of K+
conduction and selectivity, Science 280 (1998) 69–77.
[55] N. Unwin, Reﬁned structure of the nicotinic acetylcholine receptor at 4 Å
resolution, J. Mol. Biol. 346 (2005) 967–989.
[56] A.I. Sobolevsky, M.P. Rosconi, E. Gouaux, X-ray structure, symmetry and
mechanism of an AMPA-subtype glutamate receptor, Nature 462 (2009)
745–756.
[57] R.J.C. Hilf, R. Dutzler, X-ray structure of a prokaryotic pentameric ligand-gated
ion channel, Nature 452 (2008) 375–379.
[58] A.B. Waight, J. Love, D.N. Wang, Structure and mechanism of a pentameric
formate channel, Nature Struc. Biol. 17 (2010) 31–37.
[59] G. Chang, R.H. Spencer, A.T. Lee, M.T. Barclay, D.C. Rees, Structure of the MscL
homolog from Mycobacterium tuberculosis: a gated mechanosensitive ion
channel, Science 282 (1998) 2220–2226.
[60] L. Li, Z. Wang, Y. Lu, Q. Bao, S. Chen, N. Wu, S. Cheng, J. Weng, Y. Zhang, J. Yan, L.
Mei, X. Wang, H. Zhu, Y. Yu, M. Zhang, M. Li, J. Yao, Q. Lu, P. Yao, X. Bo, J. Wo, S.
Wang, S. Hu, Severe acute respiratory syndrome-associated coronavirus
genotype and its characterization, Chin. Med. J. 116 (2003) 1288–1292.
[61] J. Ishikawa, T. Kaisho, H. Tomizawa, B.O. Lee, Y. Kobune, J. Inazawa, K. Oritani, M.
Itoh, T. Ochi, K. Ishihara, T. Hirano, Molecular cloning and chromosomal mapping
of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-
cell growth, Genomics 26 (1995) 527–534.
[62] J. Krüger, W.B. Fischer, Assembly of viral membrane proteins, J. Chem. Theory
Comput. 5 (2009) 2503–2513.
571W.B. Fischer, H.-J. Hsu / Biochimica et Biophysica Acta 1808 (2011) 561–571[63] F.A. Kovacs, J.K. Denny, Z. Song, J.R. Quine, T.A. Cross, Helix tilt of the M2
transmembrane peptide from inﬂuenza A virus: an intrinsic property, J. Mol. Biol.
295 (2000) 117–125.
[64] C. Ma, F.M. Marassi, D.H. Jones, S.K. Straus, S. Bour, K. Strebel, U. Schubert, M.
Oblatt-Montal, M. Montal, S.J. Opella, Expression, puriﬁcation, and activities of
full-length and truncated versions of the integral membrane protein Vpu from
HIV-1, Prot. Sci. 11 (2002) 546–557.
[65] A.L. Stouffer, R. Acharya, D. Salom, A.S. Levine, L. Di Constanzo, C.S. Soto, V.
Tereshko, V. Nanda, S. Stayrook, W.F. DeGrado, Structural basis for the function
and inhibition of an inﬂuenza virus proton channel, Nature 451 (2008) 596–599.
[66] J.R. Schnell, J.J. Chou, Structure and mechanism of the M2 proton channel of
inﬂuenza A virus, Nature 451 (2008) 591–595.
[67] J. Wang, R.M. Pielak, M.A. McClintock, J.J. Chou, Solution structure and functional
analysis of the inﬂuenza B proton channel, Nature Struc. Biol. 16 (2009)
1267–1271.
[68] D. Clarke, S. Grifﬁn, L. Beales, C.S. Gelais, S. Burgess, M. Harris, D. Rowlands,
Evidence for the formation of a heptameric ion channel complex by the hepatitis
C virus p7 protein in vitro, J. Biol. Chem. 281 (2006) 37057–37068.
[69] A. Kukol, I.T. Arkin, Vpu transmembrane peptide structure obtained by site-
speciﬁc fourier transform infrared dichroism and global molecular dynamics
searching, Biophys. J. 77 (1999) 1594–1601.
[70] A. Kukol, P.D. Adams, L.M. Rice, A.T. Brunger, I.T. Arkin, 951–962, Experimentally
based orientational reﬁnement of membrane protein models: a structure for the
inﬂuenza A M2 H+ channel, J. Mol. Biol. 286 (1999) 951–962.
[71] L.R. Forrest, A. Kukol, I.T. Arkin, D.P. Tieleman, M.S. Sansom, Exploring models of
the inﬂuenza A M2 channel: MD simulations in a phospholipid bilayer, Biophys.
J. 78 (2000) 55–69.
[72] F. Cordes, A. Kukol, L.R. Forrest, I.T. Arkin, M.S.P. Sansom, W.B. Fischer, The
structure of the HIV-1 Vpu ion channel: modelling and simulation studies,
Biochim. Biophys. Acta 1512 (2001) 291–298.
[73] G. Patargias, N. Zitzmann, R. Dwek, W.B. Fischer, Protein–protein interactions:
modeling the hepatitis C virus ion channel p7, J. Med. Chem. 49 (2006) 648–655.
[74] S. Faham, D. Yang, E. Bare, S. Yohannan, J.P. Whitelegge, J.U. Bowie, Side-chain
contributions to membrane protein structure and stability, J. Mol. Biol. 335
(2004) 297–305.
[75] L. Bu, W. Im, C.L. Brooks III, Membrane assembly of simple helix homo-oligomers
studied via molecular dynamics simulations, Biophys. J. 92 (2007) 854–863.
[76] J. Krüger, W.B. Fischer, Structural implications of mutations assessed by molecular
dynamics: Vpu1–32 from HIV-1., Eur. Biophys. J., published online (2009).
[77] G. Patargias, H. Martay, W.B. Fischer, Reconstructing potentials of mean force
from short steeredmolecular dynamics simulations of Vpu fromHIV-1, J. Biomol.
Struc. Dyn. 26 (2009) 1–12.
[78] J.P. Ulmschneider, M. Ulmschneider, Folding simulations of the transmembrane
helix of virus protein u in an implicite membrane model, J. Chem. Theory
Comput. 3 (2007) 2335–2346.
[79] P.J. Bond, M.S.P. Sansom, Insertion and assembly of membrane proteins via
simulation, J. Am. Chem. Soc. 128 (2006) 2697–2704.
[80] C.S. Gandhi, K. Shuck, J.D. Lear, G.R. Dieckmann, W.F. DeGrado, R.A. Lamb, L.H.
Pinto, Cu(II) inhibition of the proton translocation machinery of the inﬂuenza A
virus M2 protein, J. Biol. Chem. 274 (1999) 5474–5482.
[81] M. Yi, T.A. Cross, H.-X. Zhou, A secondary gate as a mechanism for inhibition of
the M2 proton channel by amantadine, J. Phys. Chem. B 112 (2008) 7977–7979.
[82] S.D. Cady, T.V. Mishana, M. Hong, Structure of amantadine-bound M2
transmembrane peptide of inﬂuenza A in lipid bilayers from magic-angle-
spinning solid-state NMR: the role of Ser31 in amantadine binding, J. Mol. Biol.
385 (2009) 1127–1141.
[83] M.S.P. Sansom, I.D. Kerr, Inﬂuenza virus M2 protein: a molecular modelling study
on the ion channel, Protein Eng. (1993).[84] S.D. Cady, K. Schmidt-Rohr, J. Wang, C.S. Soto, W.F. DeGrado, M. Hong, Structure
of the amantadine binding site of inﬂuenza M2 proton channels in lipid bilayers,
Nature 463 (2010) 689–692.
[85] R.M. Pielak, J.J. Chou, Flu channel drug resistance: a tale of two sides, Protein Cell
1 (2010) 246–258.
[86] C. Wang, K. Takeuchi, L.H. Pinto, R.A. Lamb, Ion channel activity of inﬂuenza A
virus M2 protein: characterization of the amantadine block, J. Virol. 67 (1993)
5585–5594.
[87] X. Jing, C. Ma, Y. Ohigashi, F.A. Oliveira, T.S. Jardetzky, L.H. Pinto, R.A. Lamb,
Functional studies indicate amantadine binds to the pore of the inﬂuenza A virus
M2 proton-selective ion channel, Proc. Natl Acad. Sci. USA 105 (2008)
10967–10972.
[88] J. Wang, S.D. Cady, V. Balannik, L.H. Pinto, W.F. DeGrado, M. Hong, Discovery
of spiro-piperidine inhibitors and their modulation of the dynamics of
the M2 proton channel from inﬂuenza A virus, J. Am. Chem. Soc. 131 (2009)
8066–8076.
[89] C.G. Kim, V. Lemaitre, A. Watts, W.B. Fischer, Drug–protein interaction with Vpu
from HIV-1: proposing binding sites for amiloride and one of its derivatives,
Anal. Bioanal. Chem. 386 (2006) 2213–2217.
[90] G. Patargias, G. Ewart, C. Luscombe, W.B. Fischer, Ligand–protein docking studies
of potential HIV-1 drug compounds using the algorithm FlexX., Anal. Bioanal.
Chem., accepted (2010).
[91] W. Römer, Y.H. Lam, D. Fischer, A.Watts, W.B. Fischer, P. Göring, R.B. Wehrspohn,
U. Gösele, C. Steinem, Channel activity of a viral transmembrane peptide in
micro-BLMs: Vpu1–32 from HIV-1, J. Am. Chem. Soc. 126 (2004) 16267–16274.
[92] E. Steinmann, T. Whitﬁeld, S. Kallis, R. Dwek, N. Zitzmann, T. Pietschmann, R.
Bartenschlager, Antiviral effects of amantadine and iminosugar derivatives
against hepatitis C virus, Hepatology 46 (2007) 330–338.
[93] A. Premkumar, L. Wilson, G.D. Ewart, P.W. Gage, Cation-selective ion channels
formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride, FEBS
Lett. 557 (2004) 99–103.
[94] C.A. Luscombe, Z. Huang, M.G. Murray, M. Miller, J. Wilkinson, G.D. Ewart, A
novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral
diarrhea virus in vitro and shows synergism with recombinant interferon-α-2b
and nucleaoside analogues, Antivir. Res. 86 (2010) 144–153.
[95] S.J.D. Neil, T. Zang, P.D. Bieniasz, Tetherin inhibits retrovirus release and is
antagonized by HIV-1 Vpu, Nature 451 (2008) 425–431.
[96] N. van Damme, D. Goff, C. Katsura, R.L. Jorgensen, R. Mitchell, M.C. Johnson, E.B.
Stephens, J. Guatelli, The interferon-induced protein BST-2 restricts HIV-1
release and is downregulated from the cell surface by the viral Vpu protein, Cell
Host Microbe 3 (2008) 1–8.
[97] M. Montal, Vpu matchmakers as a therapeutic strategy for HIV infection, PLoS
Pathog. 5 (2009) e1000246.
[98] M. Porotto, P. Carta, Y. Deng, G.E. Kellogg, M. Whitt, M. Lu, B.A. Mungall, A.
Moscona, Molecular determinants of antiviral potency of paramyxovirus entry
inhibitors, J. Virol. 81 (2007) 10567–10574.
[99] J. Petersen, M. Dandri, W. Mier, M. Lütgehetmann, T. Volz, F. von Weizsäcker, U.
Haberkorn, L. Fischer, J.-M. Pollok, B. Erbes, S. Seitz, S. Urban, Prevention of
hepatitis B virus infection in vivo by entry inhibitors derived from the large
envelope protein, Nat. Biotech. (2008).
[100] M.J. Root, M.S. Kay, P.S. Kim, Protein design of an HIV-1 entry inhibitor, Science
291 (2001) 884–888.
[101] M.R. Ruff, M. Polianova, Q. Yang, G.S. Leoung, F.W. Ruscetti, C.B. Pert, Update on
D-Ala-Peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5
chemokine receptors, Curr. HIV Res. 1 (2003) 51–67.
[102] T. Strangler, T. Tran, S. Hoffmann, H. Schmidt, E. Jonas, D. Willbold, Competitive
displacement of full-length HIV-1 Nef from the Hck SH3 domain by a high-
afﬁnity artiﬁcial peptide, Biol. Chem. 388 (2007) 611–615.
